Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06194123 · ClinicalTrials.gov registry record · NA

Effect of Whitening Agent With Emulsion Gel in Saliva and Halitosis

A NA study of Xerostomia and Halitosis, sponsored by Tufts University.

Active
Registry status
NA
Development phase
27
Enrollment target
1
Study location

NCT06194123 is a NA study of Xerostomia and Halitosis that is active but no longer recruiting, run by Tufts University. The registered enrollment target is 27 participants, below the 93-participant average among 13 other Xerostomia trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06194123, a NA study of Xerostomia and Halitosis, is active but no longer recruiting, sponsored by Tufts University.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
27 participants
Enrollment target
1
Study location

Study Summary

The objective of this study is to evaluate how well the study product, Crest Daily Whitening Serum, alleviates Xerostomia and perceived halitosis over 1 week of use.

Conditions Studied

Interventions

  • OTHER Crest Daily Whitening Serum

Study Locations (1)

Massachusetts

  • Tufts University School of Dental Medicine - Boston

Trial Details

FieldValue
Enrollment Target 27 participants
Start Date 2024-02-01
Est. Completion 2027-02-01
Phase NA

Sponsor

Tufts University

163 total trials

What the Registry Record Tells You About NCT06194123

The ClinicalTrials.gov registry entry for NCT06194123 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 93-participant average among 13 other Xerostomia trials with a reported enrollment target (71% lower). The listed sponsor is Tufts University, which has 163 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Xerostomia appearing as the primary indexed condition, and to 1 intervention - of which Crest Daily Whitening Serum is the first listed.

NCT06194123 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06194123 about?

NCT06194123 is a clinical study titled "Effect of Whitening Agent With Emulsion Gel in Saliva and Halitosis". The objective of this study is to evaluate how well the study product, Crest Daily Whitening Serum, alleviates Xerostomia and perceived halitosis over 1 week of use.

What is the current status of trial NCT06194123?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 27 participants. The study started on 2024-02-01. Estimated completion is 2027-02-01.

What conditions does trial NCT06194123 study?

This clinical trial studies the following conditions: Xerostomia, Halitosis.

What interventions are being tested in trial NCT06194123?

The interventions under investigation include: Crest Daily Whitening Serum (OTHER).

Who is sponsoring clinical trial NCT06194123?

This trial is sponsored by Tufts University, which has 163 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06194123 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Xerostomia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.